¿Cómo saber qué información es fiable?

Understanding Pharmacogenetics and Evidence Levels

Importance of Evidence in Pharmacogenetics

• The lesson emphasizes the significance of evidence supporting information from databases and publications, equating it to security in assessments and advice.

PharmGKB Levels of Evidence

• The PharmGKB consortium categorizes evidence into four levels based on the relationship between genetic variants (genotype) and their effects on medication (phenotype). Level 4 indicates no evidence for a relationship.

• Level 3 suggests some evidence exists but is often based on limited studies, making it less reliable. This level reflects uncertainty regarding genotype-phenotype correlations.

• Levels 2A and 2B indicate a clearer association, though some studies may not consistently verify this link. Clinical annotations may be incomplete at this level.

• Levels 1A and 1B represent strong relationships between genetic variants and phenotypes, allowing for clear conclusions about drug effects on treatment outcomes. Higher levels indicate more reliable information sources.

Publications' Quality Assessment

• A table outlines various levels of publication quality, with Level 4 indicating no evidence while higher levels reflect good-quality publications that provide reliable data for pharmacogenetic work. Characteristics defining quality are highlighted in the presentation.

Actionability in Pharmacogenetic Recommendations

• The discussion transitions to clinical guidelines derived from pharmacogenetic data, focusing on actionability—genes that can inform patient-specific recommendations for medication adjustments or dosing changes based on genetic profiles. This is guided by the CPIC consortium's established levels of recommendation ranging from A to C, with higher levels indicating stronger recommendations supported by robust data.

• Lower-level recommendations (C downwards) lack sufficient data for clear guidance, emphasizing the need for careful consideration when advising patients based on pharmacogenetic findings. Higher-level recommendations facilitate informed decisions regarding medication modifications or dosage adjustments based on genetic insights.